Intraocular pressure elevation after intravitreal triamcinolone acetonide injection
Intraocular pressure elevation after intravitreal triamcinolone acetonide injection
复制标题
DOI：
10.1016/j.ophtha.2004.10.042
复制
发表时间：
2005-04-01
期刊：
影响因子：
13.7
通讯作者：
Kamppeter, BA
中科院分区：
文献类型：
--
作者：
Jonas, JB;Degenring, RF;Kamppeter, BA
目的：报告玻璃体内注射曲安奈德后的眼内压（IOP）。设计：对先前报告的数据和病例系列研究进行荟萃分析。参与者：该研究包括272名患者（305只眼）接受玻璃体内注射约20 mg曲安奈德作为弥漫性糖尿病黄斑水肿的治疗（n = 84名患者）、渗出性年龄相关性黄斑变性（n = 181名患者）、视网膜静脉阻塞（n = 20名患者）、葡萄膜炎（n = 9）、人工晶状体囊样黄斑水肿（n = 6）和其他原因（n = 5）。平均随访时间为10.4 ± 6.7个月（中位数：7.9个月;范围：3.0-35.7个月）。干预措施：玻璃体内注射约20 mg曲安奈德。主要结果测量：Intraocular pressure.Results：眼压读数高于21 mmHg，30 mmHg，35 mmHg，和40 mmHg，分别在112（41.2%）例，31（11.4%）例，15（5.5%）例，和5（1.8%）例患者，分别测量。除3只（1.0%）眼睛进行了滤过手术外，所有眼睛均通过抗青光眼药物治疗了含曲安奈德的IOP升高。平均IOP在注射后1周开始升高，并在注射后约8至9个月恢复至基线值。年龄较小（P = 0.029）与曲安奈德诱导的高眼压显著相关。曲安奈德反应者和曲安奈德无反应者在性别（P = 0.42）、屈光不正（P = 0.86）、糖尿病状态（P = 0.74）和treatment.Conclusions原因方面无显著差异：这些发现可能有助于比较玻璃体内曲安奈德治疗的风险和益处。(c)2005年，美国眼科学会。
Purpose: To report on intraocular pressure (IOP) after intravitreal injections of triamcinolone acetonide.Design: Meta-analysis of previously reported data and case series studies.Participants: The study included 272 patients (305 eyes) receiving an intravitreal injection of approximately 20 mg triamcinolone acetonide as treatment for diffuse diabetic macular edema (n = 84 patients), exudative age-related macular degeneration (n = 181 patients), retinal vein occlusions (n = 20 patients), uveitis (n = 9), pseudophakic cystoid macular edema (n = 6), and other reasons (n = 5). Mean follow-up was 10.4 +/- 6.7 months (median, 7.9 months; range, 3.0-35.7 months). Intervention: Intravitreal injection of approximately 20 mg triamcinolone acetonide.Main Outcome Measure: Intraocular pressure.Results: Intraocular pressure readings higher than 21 mmHg, 30 mmHg, 35 mmHg, and 40 mmHg, respectively, were measured in 112 (41.2%) patients, 31 (11.4%) patients, 15 (5.5%) patients, and 5 (1.8%) patients, respectively. Triamcinolone-incluced IOP elevation was treated by antiglaucoma medication in all but 3 (1.0%) eyes, for which filtering surgery was performed. Mean IOP started to rise 1 week after injection and returned to baseline values approximately 8 to 9 months after injection. Younger age (P = 0.029) was significantly associated with triamcinolone-induced ocular hypertension. Triamcinolone responders and triamcinolone nonresponders did not vary significantly in gender (P = 0.42), refractive error (P = 0.86), diabetes mellitus status (P = 0.74), and reason for treatment.Conclusions: These findings may be useful for comparing risks and benefits of intravitreal triamcinolone acetonide therapy. (c) 2005 by the American Academy of Ophthalmology.